DE69912313D1 - Colchinolderivate als gefässschädigende mittel - Google Patents

Colchinolderivate als gefässschädigende mittel

Info

Publication number
DE69912313D1
DE69912313D1 DE69912313T DE69912313T DE69912313D1 DE 69912313 D1 DE69912313 D1 DE 69912313D1 DE 69912313 T DE69912313 T DE 69912313T DE 69912313 T DE69912313 T DE 69912313T DE 69912313 D1 DE69912313 D1 DE 69912313D1
Authority
DE
Germany
Prior art keywords
sup
sub
compounds
formula
alkoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69912313T
Other languages
English (en)
Other versions
DE69912313T2 (de
Inventor
Peter David Davis
Jean-Claude Arnould
Francis Thomas Boyle
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiogene Pharmaceuticals Ltd
Original Assignee
Angiogene Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiogene Pharmaceuticals Ltd filed Critical Angiogene Pharmaceuticals Ltd
Publication of DE69912313D1 publication Critical patent/DE69912313D1/de
Application granted granted Critical
Publication of DE69912313T2 publication Critical patent/DE69912313T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A61K31/6615—Compounds having two or more esterified phosphorus acid groups, e.g. inositol triphosphate, phytic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
DE69912313T 1999-01-07 1999-12-24 Colchinolderivate als gefässschädigende mittel Expired - Fee Related DE69912313T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB9900334 1999-01-07
GBGB9900334.5A GB9900334D0 (en) 1999-01-07 1999-01-07 Tricylic vascular damaging agents
PCT/GB1999/004436 WO2000040529A1 (en) 1999-01-07 1999-12-24 Colchinol derivatives as vascular damaging agents

Publications (2)

Publication Number Publication Date
DE69912313D1 true DE69912313D1 (de) 2003-11-27
DE69912313T2 DE69912313T2 (de) 2004-08-26

Family

ID=10845715

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69912313T Expired - Fee Related DE69912313T2 (de) 1999-01-07 1999-12-24 Colchinolderivate als gefässschädigende mittel

Country Status (22)

Country Link
US (2) US7135502B1 (de)
EP (1) EP1140745B1 (de)
JP (1) JP2002534400A (de)
KR (1) KR20010101402A (de)
CN (1) CN1398247A (de)
AT (1) ATE252529T1 (de)
AU (1) AU760830B2 (de)
BR (1) BR9916790A (de)
CA (1) CA2355302A1 (de)
DE (1) DE69912313T2 (de)
DK (1) DK1140745T3 (de)
ES (1) ES2211206T3 (de)
GB (2) GB9900334D0 (de)
HK (1) HK1040703A1 (de)
IL (1) IL143978A0 (de)
MX (1) MXPA01006474A (de)
MY (1) MY130755A (de)
NO (1) NO20013367L (de)
NZ (1) NZ512398A (de)
PT (1) PT1140745E (de)
WO (1) WO2000040529A1 (de)
ZA (1) ZA200105065B (de)

Families Citing this family (296)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
SE9903544D0 (sv) 1999-10-01 1999-10-01 Astra Pharma Prod Novel compounds
GB2359551A (en) 2000-02-23 2001-08-29 Astrazeneca Uk Ltd Pharmaceutically active pyrimidine derivatives
AR028948A1 (es) 2000-06-20 2003-05-28 Astrazeneca Ab Compuestos novedosos
CN1255391C (zh) * 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
US6720323B2 (en) 2000-07-07 2004-04-13 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
SE0003828D0 (sv) 2000-10-20 2000-10-20 Astrazeneca Ab Novel compounds
US6919324B2 (en) 2001-10-26 2005-07-19 Oxigene, Inc. Functionalized stilbene derivatives as improved vascular targeting agents
CA2473572C (en) 2002-02-01 2011-05-10 Astrazeneca Ab Quinazoline compounds
GB0217431D0 (en) 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ES2295685T3 (es) 2002-08-24 2008-04-16 Astrazeneca Ab Derivados de pirimidina como moduladores de la actividad del receptor de quimioquinas.
GB0221828D0 (en) 2002-09-20 2002-10-30 Astrazeneca Ab Novel compound
SI1578755T1 (sl) 2002-12-24 2007-12-31 Astrazeneca Ab Fosfonooksi kinazolinski derivati in njihova farmacevtska uporaba
AU2004218412A1 (en) 2003-02-28 2004-09-16 Oxigene, Inc. Compositions and methods with enhanced therapeutic activity
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
WO2005051301A2 (en) 2003-11-19 2005-06-09 Array Biopharma Inc. Heterocyclic inhibitors of mek and methods of use thereof
GB0328243D0 (en) 2003-12-05 2004-01-07 Astrazeneca Ab Methods
GB0329771D0 (en) * 2003-12-23 2004-01-28 Angiogene Pharm Ltd Chemical processes & intermediates
EP2305671A1 (de) 2004-01-05 2011-04-06 AstraZeneca AB Thiophen- und Thiazolderivate als CHK1-Inhibitoren
SE0401657D0 (sv) 2004-06-24 2004-06-24 Astrazeneca Ab Chemical compounds
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
ES2442678T3 (es) 2004-08-28 2014-02-12 Astrazeneca Ab Derivados de pirimidín sulfonamidas como moduladores del receptor de quimioquina
EP2284194A1 (de) 2004-12-21 2011-02-16 AstraZeneca AB Antikörper gegen Angiopoietin-2 und ihre Verwendungen
GB0428100D0 (en) * 2004-12-23 2005-01-26 Astrazeneca Ab Chemical processes & intermediates
PL1846394T3 (pl) 2005-02-04 2012-04-30 Astrazeneca Ab Pochodne pirazoliloaminopirydyny użyteczne jako inhibitory kinazy
US8314127B2 (en) 2005-07-21 2012-11-20 Astrazeneca Ab Piperidine derivatives
TW200738634A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
US20090118263A1 (en) 2005-09-22 2009-05-07 Dainippon Sumitomo Pharma Co., Ltd. Novel Adenine Compound
EP1939199A4 (de) 2005-09-22 2010-10-20 Dainippon Sumitomo Pharma Co Neue adeninverbindung
WO2007034881A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JPWO2007034917A1 (ja) 2005-09-22 2009-03-26 大日本住友製薬株式会社 新規なアデニン化合物
WO2007034916A1 (ja) 2005-09-22 2007-03-29 Dainippon Sumitomo Pharma Co., Ltd. 新規アデニン化合物
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
PT1945631E (pt) 2005-10-28 2012-10-15 Astrazeneca Ab Derivados de 4-(3-aminopirazole)pirimidina para utilização como inibidores da tirosina-cinase no tratamento do cancro
DE602006021645D1 (de) 2005-11-15 2011-06-09 Array Biopharma Inc Verfahren und Zwischenverbindungen zur Herstellung von N4-Phenyl-Quinazolin-4-Amin Derivaten
TW200730512A (en) 2005-12-12 2007-08-16 Astrazeneca Ab Novel compounds
JP5302007B2 (ja) 2005-12-13 2013-10-02 アストラゼネカ アクチボラグ インスリン様増殖因子に特異的な結合タンパク質およびその使用
US20080293775A1 (en) 2005-12-15 2008-11-27 Astrazeneca Ab Substituted Diphenylethers, -Amines, -Sulfides and -Methanes for the Treatment of Respiratory Disease
TW200813091A (en) 2006-04-10 2008-03-16 Amgen Fremont Inc Targeted binding agents directed to uPAR and uses thereof
JP2009538289A (ja) 2006-05-26 2009-11-05 アストラゼネカ・アクチエボラーグ ビアリールまたはヘテロアリール置換インドール
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
DE102006037478A1 (de) 2006-08-10 2008-02-14 Merck Patent Gmbh 2-(Heterocyclylbenzyl)-pyridazinonderivate
ES2648388T3 (es) * 2006-08-23 2018-01-02 Kudos Pharmaceuticals Limited Derivados de 2-metilmorfolin pirido-, pirazo- y pirimido-pirimidina como inhibidores de mTOR
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
TW200831528A (en) 2006-11-30 2008-08-01 Astrazeneca Ab Compounds
ATE555111T1 (de) 2006-12-19 2012-05-15 Astrazeneca Ab Chinuclidinol-derivate als muscarinrezeptor- antagonisten
CL2008000191A1 (es) 2007-01-25 2008-08-22 Astrazeneca Ab Compuestos derivados de 4-amino-cinnotina-3-carboxamida; inhibidores de csf-1r quinasa; su proceso de preparacion; y su uso para tratar el cancer.
JPWO2008114819A1 (ja) 2007-03-20 2010-07-08 大日本住友製薬株式会社 新規アデニン化合物
PE20081887A1 (es) 2007-03-20 2009-01-16 Dainippon Sumitomo Pharma Co Nuevo compuesto de adenina
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
DE102007025717A1 (de) 2007-06-01 2008-12-11 Merck Patent Gmbh Arylether-pyridazinonderivate
DE102007025718A1 (de) 2007-06-01 2008-12-04 Merck Patent Gmbh Pyridazinonderivate
DE102007026341A1 (de) 2007-06-06 2008-12-11 Merck Patent Gmbh Benzoxazolonderivate
UA100983C2 (ru) 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
DE102007032507A1 (de) 2007-07-12 2009-04-02 Merck Patent Gmbh Pyridazinonderivate
DE102007038957A1 (de) 2007-08-17 2009-02-19 Merck Patent Gmbh 6-Thioxo-pyridazinderivate
DE102007041115A1 (de) 2007-08-30 2009-03-05 Merck Patent Gmbh Thiadiazinonderivate
WO2009044200A1 (en) 2007-10-04 2009-04-09 Astrazeneca Ab Steroidal [3, 2-c] pyrazole compounds, with glucocorticoid activity
MY150059A (en) 2007-10-11 2013-11-29 Astrazeneca Ab Pyrrolo [2,3-d] pyrimidin derivatives as protein kinase b inhibitors
DE102007061963A1 (de) 2007-12-21 2009-06-25 Merck Patent Gmbh Pyridazinonderivate
US8092804B2 (en) 2007-12-21 2012-01-10 Medimmune Limited Binding members for interleukin-4 receptor alpha (IL-4Rα)-173
EP3211010A1 (de) 2007-12-21 2017-08-30 Medimmune Limited Bindungselemente für interleukin-4-rezeptor-alpha (il-4r) - 173
EP2242759B1 (de) 2008-02-06 2012-09-12 AstraZeneca AB Verbindungen
US8735584B2 (en) 2008-02-28 2014-05-27 Merck Patent Gmbh Protein kinase inhibitors and use thereof
DE102008019907A1 (de) 2008-04-21 2009-10-22 Merck Patent Gmbh Pyridazinonderivate
US8273774B2 (en) 2008-05-27 2012-09-25 Astrazeneca Ab Phenoxypyridinylamide compounds
DE102008025750A1 (de) 2008-05-29 2009-12-03 Merck Patent Gmbh Dihydropyrazolderivate
DE102008028905A1 (de) 2008-06-18 2009-12-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo[4,3-b]pyridazinderivate
DE102008029734A1 (de) 2008-06-23 2009-12-24 Merck Patent Gmbh Thiazolyl-piperidinderivate
TWI461423B (zh) 2008-07-02 2014-11-21 Astrazeneca Ab 用於治療Pim激酶相關病狀及疾病之噻唑啶二酮化合物
DE102008037790A1 (de) 2008-08-14 2010-02-18 Merck Patent Gmbh Bicyclische Triazolderivate
DE102008038221A1 (de) 2008-08-18 2010-02-25 Merck Patent Gmbh 7-Azaindolderivate
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
DE102008052943A1 (de) 2008-10-23 2010-04-29 Merck Patent Gmbh Azaindolderivate
WO2010067102A1 (en) 2008-12-09 2010-06-17 Astrazeneca Ab Diazaspiro [5.5] undecane derivatives and related compounds as muscarinic-receptor antagonists and beta-adrenoreceptor agonists for the treatment of pulmonary disorders
EP2373326B1 (de) 2008-12-11 2016-03-09 Axcentua Pharmaceutucals AB Kristalline formen von genistein
US7863325B2 (en) 2008-12-11 2011-01-04 Axcentua Pharmaceuticals Ab Crystalline genistein sodium salt dihydrate
US20100152197A1 (en) 2008-12-15 2010-06-17 Astrazeneca Ab (4-tert-butylpiperazin-2-yl)(piperazin-1-yl)methanone-n-carboxamide derivatives
US9938268B2 (en) 2008-12-17 2018-04-10 Merck Patent Gmbh C-ring modified tricyclic benzonaphthiridinone protein kinase inhibitors and use thereof
DE102008063667A1 (de) 2008-12-18 2010-07-01 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-°[1,2,4]triazolo[4,3-b]pyrimidin-derivate
EP2367822B1 (de) 2008-12-18 2016-10-05 Merck Patent GmbH Tricyclische azaindole
UY32351A (es) 2008-12-22 2010-07-30 Astrazeneca Ab Compuestos de pirimidinil indol para uso como inhibidores de atr
DE102008062826A1 (de) 2008-12-23 2010-07-01 Merck Patent Gmbh Pyridazinonderivate
DE102008062825A1 (de) 2008-12-23 2010-06-24 Merck Patent Gmbh 3-(3-Pyrimidin-2-yl-benzyl)-[1,2,4]triazolo [4,3-b]pyridazin-derivate
AU2009331528A1 (en) 2008-12-23 2011-08-11 Astrazeneca Ab Targeted binding agents directed to alpha5beta1 and uses thereof
DE102009003975A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Benzothiazolonderivate
DE102009003954A1 (de) 2009-01-07 2010-07-08 Merck Patent Gmbh Pyridazinonderivate
DE102009004061A1 (de) 2009-01-08 2010-07-15 Merck Patent Gmbh Pyridazinonderivate
WO2010089580A1 (en) 2009-02-06 2010-08-12 Astrazeneca Ab Use of a mct1 inhibitor in the treatment of cancers expressing mct1 over mct4
SG172986A1 (en) 2009-02-10 2011-08-29 Astrazeneca Ab Triazolo [4,3-b] pyridazine derivatives and their uses for prostate cancer
GB0905127D0 (en) 2009-03-25 2009-05-06 Pharminox Ltd Novel prodrugs
UY32520A (es) 2009-04-03 2010-10-29 Astrazeneca Ab Compuestos que tienen actividad agonista del receptor de glucocorticoesteroides
US8389580B2 (en) 2009-06-02 2013-03-05 Duke University Arylcyclopropylamines and methods of use
US20100317593A1 (en) 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
GB0913342D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab Compounds - 801
DE102009043260A1 (de) 2009-09-28 2011-04-28 Merck Patent Gmbh Pyridinyl-imidazolonderivate
WO2011039528A1 (en) 2009-10-02 2011-04-07 Astrazeneca Ab 2-pyridone compounds used as inhibitors of neutrophil elastase
DE102009049679A1 (de) 2009-10-19 2011-04-21 Merck Patent Gmbh Pyrazolopyrimidinderivate
WO2011048409A1 (en) 2009-10-20 2011-04-28 Astrazeneca Ab Cyclic amine derivatives having beta2 adrenergic receptor agonist and muscarinic receptor antagonist activity
US8399460B2 (en) 2009-10-27 2013-03-19 Astrazeneca Ab Chromenone derivatives
WO2011062550A1 (en) 2009-11-18 2011-05-26 Astrazeneca Ab Benzoimidazole compounds and uses thereof
KR101573109B1 (ko) 2009-11-24 2015-12-01 메디뮨 리미티드 Ｂ７―ｈ１에 대한 표적화된 결합 물질
JP2013512859A (ja) 2009-12-03 2013-04-18 大日本住友製薬株式会社 トール様受容体（ｔｌｒ）を介して作用するイミダゾキノリン
MX2012006776A (es) 2009-12-14 2012-10-05 Merck Patent Gmbh Inhibidores de la esfingosina quinasa.
DE102009058280A1 (de) 2009-12-14 2011-06-16 Merck Patent Gmbh Thiazolderivate
US8907098B2 (en) 2009-12-17 2014-12-09 Merck Patent Gmbh Inhibitors of sphingosine kinase
CN103980338B (zh) 2010-01-15 2017-04-26 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
KR20120120307A (ko) 2010-01-19 2012-11-01 아스트라제네카 아베 피라진 유도체
WO2011095807A1 (en) 2010-02-07 2011-08-11 Astrazeneca Ab Combinations of mek and hh inhibitors
WO2011114148A1 (en) 2010-03-17 2011-09-22 Astrazeneca Ab 4h- [1, 2, 4] triazolo [5, 1 -b] pyrimidin-7 -one derivatives as ccr2b receptor antagonists
US20130059916A1 (en) 2010-05-26 2013-03-07 Stephane Rocchi Biguanide compounds and its use for treating cancer
WO2011154677A1 (en) 2010-06-09 2011-12-15 Astrazeneca Ab Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
SA111320519B1 (ar) 2010-06-11 2014-07-02 Astrazeneca Ab مركبات بيريميدينيل للاستخدام كمثبطات atr
GB201009801D0 (en) 2010-06-11 2010-07-21 Astrazeneca Ab Compounds 950
TW201219383A (en) 2010-08-02 2012-05-16 Astrazeneca Ab Chemical compounds
TWI535712B (zh) 2010-08-06 2016-06-01 阿斯特捷利康公司 化合物
DE102010034699A1 (de) 2010-08-18 2012-02-23 Merck Patent Gmbh Pyrimidinderivate
CN102656179B (zh) 2010-08-28 2015-07-29 苏州润新生物科技有限公司 蟾蜍灵衍生物、其药物组合物及用途
GB201016442D0 (en) 2010-09-30 2010-11-17 Pharminox Ltd Novel acridine derivatives
DE102010048800A1 (de) 2010-10-20 2012-05-10 Merck Patent Gmbh Chinoxalinderivate
DE102010049595A1 (de) 2010-10-26 2012-04-26 Merck Patent Gmbh Chinazolinderivate
WO2012067268A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Cyclic amide compounds and their use in the treatment of disease
WO2012067269A1 (en) 2010-11-19 2012-05-24 Dainippon Sumitomo Pharma Co., Ltd. Aminoalkoxyphenyl compounds and their use in the treatment of disease
WO2012066336A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Benzylamine compounds as toll -like receptor 7 agonists
WO2012066335A1 (en) 2010-11-19 2012-05-24 Astrazeneca Ab Phenol compounds als toll -like receptor 7 agonists
JP5978225B2 (ja) 2010-12-16 2016-08-24 大日本住友製薬株式会社 治療に有用なイミダゾ［４，５−ｃ］キノリン−１−イル誘導体
DK2651943T3 (en) 2010-12-17 2017-06-06 Sumitomo Dainippon Pharma Co Ltd purine derivatives
EP2655416A1 (de) 2010-12-20 2013-10-30 Medimmune Limited Anti-il-18-antikörper und ihre verwendung
US9493503B2 (en) 2011-02-02 2016-11-15 Neupharma, Inc. Certain chemical entities, compositions, and methods
ES2691673T3 (es) 2011-02-17 2018-11-28 Cancer Therapeutics Crc Pty Limited Inhibidores de Fak
DK2675794T3 (da) 2011-02-17 2019-05-06 Cancer Therapeutics Crc Pty Ltd Selektive fak-inhibitorer
GB201104267D0 (en) 2011-03-14 2011-04-27 Cancer Rec Tech Ltd Pyrrolopyridineamino derivatives
UY34013A (es) 2011-04-13 2012-11-30 Astrazeneca Ab ?compuestos de cromenona con actividad anti-tumoral?.
WO2012175991A1 (en) 2011-06-24 2012-12-27 Pharminox Limited Fused pentacyclic anti - proliferative compounds
US20140227293A1 (en) 2011-06-30 2014-08-14 Trustees Of Boston University Method for controlling tumor growth, angiogenesis and metastasis using immunoglobulin containing and proline rich receptor-1 (igpr-1)
SI3255043T1 (sl) 2011-07-12 2021-04-30 Astrazeneca Ab N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorobenziltio) pirimidin-4-il)-3-metilazetidin-1-sulfonamid, kot modulator kemokinskega receptorja
PL3686194T3 (pl) 2011-07-27 2022-01-17 Astrazeneca Ab Związki 2-(2,4,5-podstawione-anilino)pirymidynowe
JP5651271B2 (ja) 2011-07-29 2015-01-07 メディシノヴァ， インコーポレイテッド． デニブリン二塩酸塩
DE102011111400A1 (de) 2011-08-23 2013-02-28 Merck Patent Gmbh Bicyclische heteroaromatische Verbindungen
WO2013032951A1 (en) 2011-08-26 2013-03-07 Neupharma, Inc. Certain chemical entities, compositions, and methods
CN104080335B (zh) 2011-09-01 2017-06-09 钱向平 某些化学实体、组合物及方法
JP6093768B2 (ja) 2011-09-14 2017-03-08 ニューファーマ， インコーポレイテッド 特定の化学的実体、組成物、および方法
WO2013043935A1 (en) 2011-09-21 2013-03-28 Neupharma, Inc. Certain chemical entites, compositions, and methods
EP2760458B1 (de) 2011-09-29 2017-06-14 The University of Liverpool Prävention und/oder behandlung von krebs und/oder krebsmetastasen
WO2013049701A1 (en) 2011-09-30 2013-04-04 Neupharma, Inc. Certain chemical entities, compositions, and methods
US20130178520A1 (en) 2011-12-23 2013-07-11 Duke University Methods of treatment using arylcyclopropylamine compounds
WO2013112950A2 (en) 2012-01-25 2013-08-01 Neupharma, Inc. Certain chemical entities, compositions, and methods
KR20140117636A (ko) 2012-01-28 2014-10-07 메르크 파텐트 게엠베하 트리아졸로[4,5-ｄ]피리미딘 유도체
SI2812337T1 (sl) 2012-02-09 2017-01-31 Merck Patent Gmbh Furo (3,2-b) in tieno (3,2-b) piridinski derivati kot zaviralci tbk1 in ikk
WO2013117288A1 (en) 2012-02-09 2013-08-15 Merck Patent Gmbh Tetrahydro-quinazolinone derivatives as tank and parp inhibitors
WO2013124025A1 (en) 2012-02-21 2013-08-29 Merck Patent Gmbh Furopyridine derivatives
ES2674451T3 (es) 2012-02-21 2018-06-29 Merck Patent Gmbh 2-amino-[1,2,4]triazolo[1,5-a] pirazinas 8-sustituidos como inhibidores de la SYK tirosina quinasa e inhibidores de la serina quinasa GCN2
JP6059260B2 (ja) 2012-02-21 2017-01-11 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ 環状ジアミノピリジン誘導体
US20150051202A1 (en) 2012-03-07 2015-02-19 Merck Patent Gmbh Triazolopyrazine derivatives
CN104169284B (zh) 2012-03-28 2017-03-29 默克专利股份公司 双环吡嗪酮衍生物
WO2013144532A1 (en) 2012-03-30 2013-10-03 Astrazeneca Ab 3 -cyano- 5 -arylamino-7 -cycloalkylaminopyrrolo [1, 5 -a] pyrimidine derivatives and their use as antitumor agents
BR112014024903A2 (pt) 2012-04-05 2017-07-11 Hoffmann La Roche anticorpos biespecíficos contra tweak humanao e il17 humana e seus usos
CN104427873B (zh) 2012-04-29 2018-11-06 润新生物公司 某些化学个体、组合物及方法
MX357502B (es) 2012-05-04 2018-07-12 Merck Patent Gmbh Derivados de pirrolotriazinona.
GB201211021D0 (en) 2012-06-21 2012-08-01 Cancer Rec Tech Ltd Pharmaceutically active compounds
WO2014015934A1 (de) 2012-07-24 2014-01-30 Merck Patent Gmbh Hydroxystatin-derivate zur behandlung von arthrose
ES2618004T3 (es) 2012-08-07 2017-06-20 Merck Patent Gmbh Derivados de piridopirimidina como inhibidores de proteínas quinasas
ES2773272T3 (es) 2012-08-08 2020-07-10 Merck Patent Gmbh Derivados de (aza-)isoquinolinona
US9238644B2 (en) 2012-08-17 2016-01-19 Cancer Therapeutics Crc Pty Limited VEGFR3 inhibitors
CN102898330B (zh) * 2012-09-03 2015-02-25 浙江大学 秋水仙碱衍生物
WO2014041349A1 (en) 2012-09-12 2014-03-20 Cancer Therapeutics Crc Pty Ltd Tetrahydropyran-4-ylethylamino- or tetrahydropyranyl-4-ethyloxy-pyrimidines or -pyridazines as isoprenylcysteincarboxymethyl transferase inhibitors
WO2014047648A1 (en) 2012-09-24 2014-03-27 Neupharma, Inc. Certain chemical entities, compositions, and methods
SG11201502120XA (en) 2012-09-26 2015-04-29 Merck Patent Gmbh Quinazolinone derivatives as parp inhibitors
US10253107B2 (en) 2012-10-26 2019-04-09 The University Of Queensland Use of endocytosis inhibitors and antibodies for cancer therapy
CN104903467B (zh) 2012-11-05 2020-09-08 Gmdx私人有限公司 确定体细胞突变原因的方法
EP2916838B1 (de) 2012-11-12 2019-03-13 Neupharma, Inc. Bestimmte chemische stoffe, zusammensetzungen und verfahren
US9732032B2 (en) 2012-11-16 2017-08-15 Merck Patent Gmbh 3-aminocyclopentane carboxamide derivatives
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
CA2898665C (en) 2013-01-31 2021-02-16 Neomed Institute Imidazopyridine compounds and their use as p2x purinoreceptor modulators
CA2902080A1 (en) 2013-02-25 2014-08-28 Merck Patent Gmbh 2-amino-3,4-dihydroquinazoline derivatives and the use thereof as cathepsin d inhibitors
EP2964648B1 (de) 2013-03-05 2016-11-16 Merck Patent GmbH 9-(aryl oder heteroaryl)-2-(pyrazolyl, pyrrolidinyl oder cyclopentyl)aminopurin-derivate als antikrebsmittel
CN113398147A (zh) 2013-03-15 2021-09-17 纽罗森特里亚股份有限公司 用于癌症的镁组合物及其用途
AR095443A1 (es) 2013-03-15 2015-10-14 Fundación Centro Nac De Investig Oncológicas Carlos Iii Heterociclos condensados con acción sobre atr
AU2014228822A1 (en) 2013-03-15 2015-10-01 Memorial Sloan-Kettering Cancer Center HSP90-targeted cardiac imaging and therapy
WO2014161570A1 (en) 2013-04-03 2014-10-09 Roche Glycart Ag Antibodies against human il17 and uses thereof
EP3004073A1 (de) 2013-06-07 2016-04-13 Université catholique de Louvain 3-carboxy-substituierte cumarinderivate mit potenzieller eignung zur behandlung von krebserkrankungen
AU2014302038B2 (en) 2013-06-25 2019-11-14 Epiaxis Therapeutics Pty Ltd Methods and compositions for modulating cancer stem cells
KR102339228B1 (ko) 2013-08-23 2021-12-13 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
AU2014324092B2 (en) 2013-09-18 2020-02-06 Epiaxis Therapeutics Pty Ltd Stem cell modulation II
US20160298197A1 (en) 2013-10-01 2016-10-13 Queensland University Of Technology Kits and methods for diagnosis, screening, treatment and disease monitoring
US8986691B1 (en) 2014-07-15 2015-03-24 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
US8980273B1 (en) 2014-07-15 2015-03-17 Kymab Limited Method of treating atopic dermatitis or asthma using antibody to IL4RA
GB201403536D0 (en) 2014-02-28 2014-04-16 Cancer Rec Tech Ltd Inhibitor compounds
CA2958704A1 (en) 2014-08-25 2016-03-03 University Of Canberra Compositions for modulating cancer stem cells and uses therefor
CA2967869A1 (en) 2014-11-17 2016-05-26 The University Of Queensland Glycoprotein biomarkers for esophageal adenocarcinoma and barrett's esophagus and uses thereof
MA41179A (fr) 2014-12-19 2017-10-24 Cancer Research Tech Ltd Composés inhibiteurs de parg
GB201501870D0 (en) 2015-02-04 2015-03-18 Cancer Rec Tech Ltd Autotaxin inhibitors
GB201502020D0 (en) 2015-02-06 2015-03-25 Cancer Rec Tech Ltd Autotaxin inhibitory compounds
US10947201B2 (en) 2015-02-17 2021-03-16 Neupharma, Inc. Certain chemical entities, compositions, and methods
GB201510019D0 (en) 2015-06-09 2015-07-22 Cancer Therapeutics Crc Pty Ltd Compounds
EP3331880B3 (de) 2015-08-04 2023-01-11 Aucentra Therapeutics Pty Ltd N-(pyridin-2-yl) -4-(thiazol-5-yl) pyrimidin-2-aminderivate als therapeutische verbindungen
WO2017031551A1 (en) 2015-08-26 2017-03-02 Gmdx Co Pty Ltd Methods of detecting cancer recurrence
AU2017214761B2 (en) 2016-02-01 2024-02-01 Epiaxis Therapeutics Pty Ltd Proteinaceous compounds and uses therefor
EP4071174A1 (de) 2016-02-15 2022-10-12 AstraZeneca AB Verfahren mit fixer intermittierender dosierung von cediranib
DK3442535T3 (da) 2016-04-15 2022-09-05 Cancer Research Tech Ltd Heterocykliske stoffer som as ret-kinase-hæmmere
GB2554333A (en) 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
MX2019001223A (es) 2016-07-29 2019-11-11 Flx Bio Inc Moduladores de receptores de quimioquina y usos de los mismos.
CN109843858B (zh) 2016-08-15 2023-05-05 润新生物公司 某些化学实体、组合物及方法
EP3515903B1 (de) 2016-09-22 2020-10-21 Cancer Research Technology Limited Zubereitung und verwendungen von pyrimidinonderivaten
GB201617103D0 (en) 2016-10-07 2016-11-23 Cancer Research Technology Limited Compound
US10786502B2 (en) 2016-12-05 2020-09-29 Apros Therapeutics, Inc. Substituted pyrimidines containing acidic groups as TLR7 modulators
MX2019006333A (es) 2016-12-05 2019-09-26 Apros Therapeutics Inc Compuestos de pirimidina que contienen grupos ácidos.
CN110418789B (zh) 2017-02-01 2022-03-25 常州千红生化制药股份有限公司 作为治疗剂的N-环烷基/杂环烷基-4-(咪唑并[1,2-a]吡啶)嘧啶-2-胺的衍生物
EP3592730B1 (de) 2017-03-09 2021-08-04 Truly Translational Sweden AB Prodrugs von sulfasalazin, pharmazeutische zusammensetzungen davon und deren verwendung in der behandlung von autoimmunkrankheiten
GB201704325D0 (en) 2017-03-17 2017-05-03 Argonaut Therapeutics Ltd Compounds
GB201705971D0 (en) 2017-04-13 2017-05-31 Cancer Res Tech Ltd Inhibitor compounds
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
CN108864079B (zh) 2017-05-15 2021-04-09 深圳福沃药业有限公司 一种三嗪化合物及其药学上可接受的盐
US11161839B2 (en) 2017-05-26 2021-11-02 The Institute Of Cancer Research: Royal Cancer Hospital 2-quinolone derived inhibitors of BCL6
ES2897200T3 (es) 2017-05-31 2022-02-28 Amplio Pharma Ab Una composición farmacéutica que comprende una combinación de metotrexato y novobiocina, y el uso de la composición en terapia
US11400160B2 (en) 2017-07-05 2022-08-02 E.P.O.S Iasis Research And Development Limited Multifunctional conjugates
HRP20230251T1 (hr) 2017-08-01 2023-04-14 Merck Patent Gmbh Derivati tiazolopridina kao antagonisti adenozinskih receptora
CN111278840B (zh) 2017-08-18 2023-11-17 癌症研究科技有限公司 吡咯并[2，3-b]吡啶化合物及其治疗癌症的用途
BR112020003594A2 (pt) 2017-08-21 2020-09-01 Merck Patent Gmbh derivados de benzimidazol como antagonistas de receptor de adenosina
WO2019038214A1 (en) 2017-08-21 2019-02-28 Merck Patent Gmbh QUINOXALINE DERIVATIVES AS ADENOSINE RECEPTOR ANTAGONISTS
TWI702205B (zh) 2017-10-06 2020-08-21 ***聯邦商拜奧卡德聯合股份公司 表皮生長因子受體抑制劑
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
NL2019801B1 (en) 2017-10-25 2019-05-02 Univ Leiden Delivery vectors
KR20200104291A (ko) 2017-11-06 2020-09-03 랩트 테라퓨틱스, 인크. 항암제
DK3488868T3 (da) 2017-11-23 2023-11-27 Medac Ges Fuer Klinische Spezialpraeparate Mbh Farmaceutisk sammensætning til oral indgivelse, som indeholder sulfasalazin og/eller et organisk sulfasalazinsalt, fremstillingsfremgangsmåde samt anvendelse
EP3489222A1 (de) 2017-11-23 2019-05-29 medac Gesellschaft für klinische Spezialpräparate mbH Sulfasalazinesalze, herstellungsverfahren und verwendungen
WO2019136514A1 (en) 2018-01-15 2019-07-18 University Of South Australia 5-(pyrimidin-4-yl)thiazol-2-yl urea derivatives as therapeutic agents
GB201801128D0 (en) 2018-01-24 2018-03-07 Univ Oxford Innovation Ltd Compounds
JP7355758B2 (ja) 2018-01-26 2023-10-03 ラプト・セラピューティクス・インコーポレイテッド ケモカイン受容体調節剤及びその使用
KR20200143361A (ko) 2018-02-08 2020-12-23 뉴파마, 인크. 특정 화학 물질, 조성물, 및 방법
WO2019175093A1 (en) 2018-03-12 2019-09-19 Astrazeneca Ab Method for treating lung cancer
DK3774817T3 (da) 2018-04-13 2023-02-13 Cancer Research Tech Ltd Bcl6-hæmmere
JP7427655B2 (ja) 2018-04-27 2024-02-05 スプルース バイオサイエンシーズ，インク． 精巣副腎残存腫瘍および卵巣副腎残存腫瘍を処置するための方法
US10857153B2 (en) 2018-06-04 2020-12-08 Apros Therapeutics, Inc. Pyrimidine compounds containing acidic groups
GB201809102D0 (en) 2018-06-04 2018-07-18 Univ Oxford Innovation Ltd Compounds
WO2019236631A1 (en) 2018-06-05 2019-12-12 Rapt Therapeutics, Inc. Pyrazolo-pyrimidin-amino-cycloalkyl compounds and their therapeutic uses
GB201810092D0 (en) 2018-06-20 2018-08-08 Ctxt Pty Ltd Compounds
GB201810581D0 (en) 2018-06-28 2018-08-15 Ctxt Pty Ltd Compounds
WO2020068600A1 (en) 2018-09-24 2020-04-02 Rapt Therapeutics, Inc. Ubiquitin-specific-processing protease 7 (usp7) modulators and uses thereof
AU2019363662A1 (en) 2018-10-25 2021-03-25 Merck Patent Gmbh 5-azaindazole derivatives as adenosine receptor antagonists
JP2022505872A (ja) 2018-10-25 2022-01-14 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング アデノシン受容体アンタゴニストとしての５－アザインダゾール誘導体
GB201819126D0 (en) 2018-11-23 2019-01-09 Cancer Research Tech Ltd Inhibitor compounds
AR117844A1 (es) 2019-01-22 2021-09-01 Merck Patent Gmbh Derivados de tiazolopiridina como antagonistas del receptor de adenosina
CN113795483A (zh) 2019-03-07 2021-12-14 默克专利有限公司 作为shp2拮抗剂的甲酰胺-嘧啶衍生物
CN111747931A (zh) 2019-03-29 2020-10-09 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物
US20230085408A1 (en) 2019-04-05 2023-03-16 STORM Therapeutics Ltd. Mettl3 inhibitory compounds
CN113646049A (zh) 2019-04-08 2021-11-12 默克专利有限公司 作为shp2拮抗剂的嘧啶酮衍生物
GB201905328D0 (en) 2019-04-15 2019-05-29 Azeria Therapeutics Ltd Inhibitor compounds
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
GB201908885D0 (en) 2019-06-20 2019-08-07 Storm Therapeutics Ltd Therapeutic compounds
JP2022545930A (ja) 2019-08-31 2022-11-01 上海奕拓醫藥科技有限責任公司 Ｆｇｆｒ阻害剤とするピラゾール類誘導体及びその調製方法
AU2020348489A1 (en) 2019-09-20 2022-05-05 Ideaya Biosciences, Inc. 4-substituted indole and indazole sulfonamido derivatives as PARG inhibitors
GB201913988D0 (en) 2019-09-27 2019-11-13 Celleron Therapeutics Ltd Novel treatment
GB201914860D0 (en) 2019-10-14 2019-11-27 Cancer Research Tech Ltd Inhibitor compounds
GB201915828D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915831D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
GB201915829D0 (en) 2019-10-31 2019-12-18 Cancer Research Tech Ltd Compounds, compositions and therapeutic uses thereof
US20230116403A1 (en) 2019-12-02 2023-04-13 Storm Therapeutics Limited Polyheterocyclic compounds as mettl3 inhibitors
GB202004960D0 (en) 2020-04-03 2020-05-20 Kinsenus Ltd Inhibitor compounds
GB202008201D0 (en) 2020-06-01 2020-07-15 Neophore Ltd Inhibitor compounds
GB202012482D0 (en) 2020-08-11 2020-09-23 Univ Of Huddersfield Novel compounds and therapeutic uses thereof
GB202012969D0 (en) 2020-08-19 2020-09-30 Univ Of Oxford Inhibitor compounds
WO2022074379A1 (en) 2020-10-06 2022-04-14 Storm Therapeutics Limited Mettl3 inhibitory compounds
WO2022074391A1 (en) 2020-10-08 2022-04-14 Storm Therapeutics Limited Compounds inhibitors of mettl3
GB202102895D0 (en) 2021-03-01 2021-04-14 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
US11918582B2 (en) 2021-03-15 2024-03-05 Rapt Therapeutics, Inc. Pyrazole pyrimidine compounds and uses thereof
WO2022233718A2 (en) 2021-05-03 2022-11-10 Merck Patent Gmbh Her2 targeting fc antigen binding fragment-drug conjugates
IL308518A (en) 2021-05-17 2024-01-01 Hk Inno N Corp History of benzamide, a method for their preparation and a pharmaceutical preparation for use in the prevention or treatment of cancer containing them as an active ingredient
CA3221411A1 (en) 2021-05-25 2022-12-01 Merck Patent Gmbh Egfr targeting fc antigen binding fragment-drug conjugates
GB202107907D0 (en) 2021-06-02 2021-07-14 Storm Therapeutics Ltd Combination therapies
GB202108383D0 (en) 2021-06-11 2021-07-28 Argonaut Therapeutics Ltd Compounds useful in the treatment or prevention of a prmt5-mediated disorder
GB202110373D0 (en) 2021-07-19 2021-09-01 Neophore Ltd Inhibitor compounds
IT202100023357A1 (it) 2021-09-09 2023-03-09 Cheirontech S R L Peptidi con attività anti-angiogenica
AU2022359801A1 (en) 2021-10-04 2024-02-01 Forx Therapeutics Ag Parg inhibitory compounds
WO2023057394A1 (en) 2021-10-04 2023-04-13 Forx Therapeutics Ag N,n-dimethyl-4-(7-(n-(1-methylcyclopropyl)sulfamoyl)-imidazo[1,5-a]pyridin-5-yl)piperazine-1-carboxamide derivatives and the corresponding pyrazolo[1,5-a]pyridine derivatives as parg inhibitors for the treatment of cancer
GB202117225D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Protac compounds
GB202117224D0 (en) 2021-11-29 2022-01-12 Neophore Ltd Inhibitor compounds
WO2023131690A1 (en) 2022-01-10 2023-07-13 Merck Patent Gmbh Substituted heterocycles as hset inhibitors
GB202202006D0 (en) 2022-02-15 2022-03-30 Chancellor Masters And Scholars Of The Univ Of Oxford Anti-cancer treatment
GB202202199D0 (en) 2022-02-18 2022-04-06 Cancer Research Tech Ltd Compounds
WO2023175185A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
WO2023175184A1 (en) 2022-03-17 2023-09-21 Forx Therapeutics Ag 2,4-dioxo-1,4-dihydroquinazoline derivatives as parg inhibitors for the treatment of cancer
GB202204935D0 (en) 2022-04-04 2022-05-18 Cambridge Entpr Ltd Nanoparticles
US20230322741A1 (en) 2022-04-06 2023-10-12 Rapt Therapeutics, Inc. Chemokine receptor modulators and uses thereof
WO2023218201A1 (en) 2022-05-11 2023-11-16 Cancer Research Technology Limited Ikk inhibitors
GB202209404D0 (en) 2022-06-27 2022-08-10 Univ Of Sussex Compounds
WO2024030825A1 (en) 2022-08-01 2024-02-08 Neupharma, Inc Crystalline salts of crystalline salts of (3s,5r,8r,9s,10s,13r,14s,17r)-14-hydroxy-10,13-dimethyl-17-(2- oxo-2h-pyran-5-yl)hexadecahydro-1h-cyclopenta[a]phenanthren-3-yl piperazine-1-carboxylate
GB202213163D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213164D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213167D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
GB202213162D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Prodrugs
GB202213166D0 (en) 2022-09-08 2022-10-26 Cambridge Entpr Ltd Novel compounds, compositions and therapeutic uses thereof
WO2024074497A1 (en) 2022-10-03 2024-04-11 Forx Therapeutics Ag Parg inhibitory compound

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3442953A (en) 1963-06-19 1969-05-06 Roussel Uclaf Novel 7-oxo-7-desacetylaminocolchicine compounds
FR4685M (de) * 1965-07-01 1966-12-19
IT1270124B (it) 1994-10-05 1997-04-28 Indena Spa Derivati della colchicina e loro impiego terapeutico
US5561122A (en) 1994-12-22 1996-10-01 Arizona Board Of Regents Acting On Behalf Of Arizona State University Combretastatin A-4 prodrug
IT1276996B1 (it) 1995-06-27 1997-11-04 Indena Spa Derivati della colchicina, loro uso e formulazioni che li contengono
US5760092A (en) * 1995-09-13 1998-06-02 Brandeis University Allocolchinones and uses thereof
IT1283110B1 (it) 1996-06-07 1998-04-07 Indena Spa Composti a scheletro colchicinico,loro uso come farmaci e composizioni che li contengono
IT1291550B1 (it) 1997-04-11 1999-01-11 Indena Spa Derivati della colchicina e della tiocolchicina ad attivita' antinfiammatoria e miorilassante
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
EP1152764A4 (de) 1999-02-18 2005-03-23 Oxigene Inc Zusammenstellungen und methoden zur verwendung in der zielung der vaskularen zerstörung
MXPA02012903A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como inhibidores de angiogenesis.
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物

Also Published As

Publication number Publication date
MY130755A (en) 2007-07-31
US20060128633A1 (en) 2006-06-15
KR20010101402A (ko) 2001-11-14
DK1140745T3 (da) 2004-02-23
GB9900334D0 (en) 1999-02-24
IL143978A0 (en) 2002-04-21
DE69912313T2 (de) 2004-08-26
CN1398247A (zh) 2003-02-19
JP2002534400A (ja) 2002-10-15
ATE252529T1 (de) 2003-11-15
AU760830B2 (en) 2003-05-22
ZA200105065B (en) 2002-09-20
GB9930610D0 (en) 2000-02-16
EP1140745A1 (de) 2001-10-10
HK1040703A1 (zh) 2002-06-21
NO20013367D0 (no) 2001-07-06
EP1140745B1 (de) 2003-10-22
US7135502B1 (en) 2006-11-14
BR9916790A (pt) 2001-12-04
WO2000040529A1 (en) 2000-07-13
NO20013367L (no) 2001-09-05
AU1882300A (en) 2000-07-24
NZ512398A (en) 2003-11-28
ES2211206T3 (es) 2004-07-01
MXPA01006474A (es) 2003-06-06
CA2355302A1 (en) 2000-07-13
PT1140745E (pt) 2004-03-31

Similar Documents

Publication Publication Date Title
DE69912313D1 (de) Colchinolderivate als gefässschädigende mittel
NZ337118A (en) 3-piperidyl-4-oxoquinazoline derivatives and pharmaceutical compositions comprising the same useful in treating or preventing arteriosclerotic and/or hyper-lipemia disease, pancreatitis, obesity, hypercholesterolemia and hypertriglyceridemia.
AU2003225617A1 (en) Thiadiazolylpiperazine derivatives useful for treating or preventing pain
ATE219363T1 (de) Lösliche prodrugs von paclitaxel
ID26179A (id) Turunan-turunan benzenasulfonamida dan penggunaannya sebagai obat-obatan
ATE286501T1 (de) Pyrimidinderivate
TR200001399T2 (tr) Siklik amin türevleri ve ilaç olarak kullanımları.
HUP0400710A2 (hu) Tioéter helyettesítővel helyettesített imidazokinolinszármazékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
WO2005056524A3 (en) Therapeutic agents useful for treating pain
RU94044436A (ru) Способы подавления атрофии кожи и влагалища
HUP0102602A2 (hu) Diacil-hidrazinszármazékok, előállításuk és alkalmazásuk, valamint e vegyületeket tartalmazó gyógyászati készítmények
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
YU42397A (sh) Korišćenje raloksifena za pripremu leka
TR200101163T2 (tr) Safra suyu ikameli fenil-alkenoilguanidinler, üretim yöntemleri, kullanımları
ES2135695T3 (es) Derivados de aminoacidos y su uso como inhibidores de la fosfolipasa a2.
SE9903611D0 (sv) Novel compounds III
TR200200485T2 (tr) Yeni A-500359 türevleri.
ATE344237T1 (de) Hydroxyacetamidobenzolsulfonamidderivate
BR0112338A (pt) Composto, composição farmacêutica, e, uso de um composto
EA200600022A1 (ru) Применение производных бицикло [2.2.1] гептана для приготовления нейропротекторных фармацевтических композиций
AP9801235A0 (en) Erythromycin derivatives.
TR199802665T2 (xx) Piperidin asetik asit t�revleri ve bunlar�n trombotik hastal�klar�n tedavisinde kullan�m�.
EA200100344A2 (ru) Новые циклобутаиндолкарбоксамидные производные, способ их получения и содержащие их фармацевтические композиции
SE9903610D0 (sv) Novel compounds II
SE9903609D0 (sv) Novel compounds I

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee